NASDAQ:ATAI atai Life Sciences (ATAI) Stock Price, News & Analysis $4.26 +0.09 (+2.16%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$4.24 -0.01 (-0.35%) As of 06:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About atai Life Sciences Stock (NASDAQ:ATAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get atai Life Sciences alerts:Sign Up Key Stats Today's Range$4.01▼$4.4050-Day Range$2.02▼$4.2652-Week Range$1.03▼$4.40Volume7.34 million shsAverage Volume7.01 million shsMarket Capitalization$853.45 millionP/E RatioN/ADividend YieldN/APrice Target$11.25Consensus RatingBuy Company Overview Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. Read More atai Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreATAI MarketRank™: atai Life Sciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 765th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.7 / 5Analyst RatingBuy Consensus Ratingatai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coverageatai Life Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about atai Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of atai Life Sciences is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of atai Life Sciences is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratioatai Life Sciences has a P/B Ratio of 6.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about atai Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.80% of the float of atai Life Sciences has been sold short.Short Interest Ratio / Days to Coveratai Life Sciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in atai Life Sciences has recently increased by 58.78%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldatai Life Sciences does not currently pay a dividend.Dividend Growthatai Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.80% of the float of atai Life Sciences has been sold short.Short Interest Ratio / Days to Coveratai Life Sciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in atai Life Sciences has recently increased by 58.78%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment-0.52 News Sentimentatai Life Sciences has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for atai Life Sciences this week, compared to 3 articles on an average week.Search Interest27 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows22 people have added atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 450% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, atai Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders26.80% of the stock of atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of atai Life Sciences is held by institutions.Read more about atai Life Sciences' insider trading history. Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATAI Stock News HeadlinesMaxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PTAugust 4 at 2:20 PM | msn.comH.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10July 31, 2025 | msn.comOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas. | InvestorPlace (Ad)ATAI Life Sciences (ATAI) Gets a Buy from TD CowenJuly 30, 2025 | theglobeandmail.comOppenheimer Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Outperform RecommendationJuly 30, 2025 | msn.comAtai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline FocusJuly 28, 2025 | seekingalpha.comAtai backs away from schizophrenia drug after trial failureJuly 28, 2025 | finance.yahoo.comATAI Life Sciences (ATAI) Stock Plunge on Trial Failure NewsJuly 28, 2025 | finance.yahoo.comSee More Headlines ATAI Stock Analysis - Frequently Asked Questions How have ATAI shares performed this year? atai Life Sciences' stock was trading at $1.33 on January 1st, 2025. Since then, ATAI shares have increased by 220.3% and is now trading at $4.26. How were atai Life Sciences' earnings last quarter? atai Life Sciences N.V. (NASDAQ:ATAI) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. The firm had revenue of $1.56 million for the quarter. When did atai Life Sciences IPO? atai Life Sciences (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are atai Life Sciences' major shareholders? Top institutional shareholders of atai Life Sciences include AdvisorShares Investments LLC (0.19%), Kingswood Wealth Advisors LLC (0.03%), Capital Advisors Inc. OK (0.02%) and PTM Wealth Management LLC (0.01%). Insiders that own company stock include Apeiron Investment Group Ltd, Life Sciences NV Atai, Florian Brand, Anne Nagengast Johnson, Sahil Kirpekar and Srinivas Rao. View institutional ownership trends. How do I buy shares of atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings5/14/2025Today8/05/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATAI CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for atai Life Sciences$11.25 High Price Target$15.00 Low Price Target$5.00 Potential Upside/Downside+164.1%Consensus RatingBuy Rating Score (0-4)3.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.27 million Net MarginsN/A Pretax Margin-7,999.62% Return on Equity-102.10% Return on Assets-77.55% Debt Debt-to-Equity Ratio0.08 Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual Sales$310 thousand Price / Sales2,753.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book6.17Miscellaneous Outstanding Shares200,340,000Free Float146,647,000Market Cap$853.45 million OptionableOptionable Beta1.54 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ATAI) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding atai Life Sciences N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.